Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 31;18:357. doi: 10.1186/s12879-018-3268-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 1 — Mean variations of total cholesterol (TC), HDL cholesterol (HDL), TC/HDL ratio, LDL cholesterol (LDL) and median variation of triglycerides (TG) from baseline (BL), to 6 and 12 months of follow up (T1 and T2, respectively) for each switch group (A-F). Tables below each graph show the number of observations at each time-point. Only patients with observations at T1 or T1/T2 are considered in the graph. A: switch from 2 nucleoside reverse transcriptase inhibitors (NRTI) + efavirenz to 2NRTI + dolutegrvir; B: switch from 2NRTI + efavirenz to 2NRTI + elvitegravir; C: switch from 2NRTI + efavirenz to 2NRTI + rilpivirine; D: switch from 2NRTI + protease inhibitors to 2NRTI + dolutegravir; E: switch from 2NRTI + protease inhibitors to 2NRTI + elvitegravir; D: switch from 2NRTI + protease inhibitors to 2NRTI + rilpivirine